|

Tremelimumab Plus Durvalumab (MEDI4736) Clinical Trials

1 actively recruiting trial

Also known as: Imfinzi®, Imjudo

Pipeline

Phase 1/2: 1

Top Sponsors

  • Yoon Jun Kim1

Indications

  • Liver Disease1
  • Hepatocellular Carcinoma (HCC)1
  • Unresectable Hepatocellular Carcinoma1
  • Liver Cancer1
  • Cancer1

Other1 trial

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.